Loading
Review on Trastuzumab deruxtecan in Triple-negative breast cancer, in Expert opinion on biological therapy (2021), one of the most cited Europe PMC records with Trastuzumab deruxtecan in its title.
Introduction: Metastatic triple-negative breast cancers (mTNBC) are characterized by aggressive behavior and worse clinical outcomes than other breast cancer subtypes, as well as poor response to cytotoxic chemotherapies. The use of antibody-drug conjugates (ADCs) has been investigated as a potential treatment strategy, particularly in heavily pretreated disease.
Areas covered: This article reviews the preclinical and clinical data supporting the use of the ADCs sacituzumab govitecan (SG), ladiratuzumab vedotin (LV), and trastuzumab deruxtecan (T-DXd) in mTNBC, and highlights ongoing clinical trials and future clinical applications.
Expert opinion: SG, LV, and T-DXd have demonstrated their potential to meaningfully improve clinical outcomes in patients with pretreated mTNBC, as demonstrated by notable response rates in phase I/II and, for SG, phase III clinical trials. Investigation of their use in combination with other agents, including PARP inhibitors and checkpoint inhibitors, is ongoing in the metastatic setting, and their application in early-stage TNBCs are under investigation. ADCs are therefore expected to redefine treatment paradigms in TNBC.
Indexed on Europe PMC as PubMed record 33089726 (DOI 10.1080/14712598.2021.1840547). Its title names Trastuzumab deruxtecan and its text names Triple-negative breast cancer; PubMed types it as a review (Review). It was matched automatically to the idea "AI quantification of HER2-low and HER2-ultralow" and no figure has been checked by an editor.
One of the most cited reviews Europe PMC returns for Trastuzumab deruxtecan in Triple-negative breast cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.